主要文件

查看所有文档

21-1430

烟酸

Name: 烟酸
Brand: SAJ

SAJ special grade, ≥99.5%

别名:

3-吡啶甲酸, 吡啶-3-羧酸, 尼亚生, 抗糙皮病因子, 维生素 B₃

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₆H₅NO₂

化学文摘社编号:

59-67-6

分子量:

123.11

EC Number:

200-441-0

UNSPSC Code:

12352005

PubChem Substance ID:

329752092

Beilstein/REAXYS Number:

109591

MDL number:

MFCD00006391

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

SAJ special grade

assay

≥99.5%

form

powder

availability

available only in Japan

color

white

mp

236-239 °C (lit.)

solubility

ethanol: 12.5 g/L at 25 °C, water: soluble 180 g/L at 20 °C

density

1.473 g/cm³ at 25 °C

SMILES string

OC(=O)c1cccnc1

InChI

1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

InChI key

PVNIIMVLHYAWGP-UHFFFAOYSA-N

说明

Still not finding the right product?

Explore all of our products under 烟酸

pictograms

GHS07

signalword

Warning

hcodes

H319

pcodes

P280 - P305 + P351 + P338 - P337 + P313

Hazard Classifications

Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

379.4 °F - closed cup

flash_point_c

193 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.

Koon K Teo et al.

Stroke, 44(10), 2688-2693 (2013-07-25)

In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

John R Guyton et al.

Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)

This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a

Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.

Martina Lukasova et al.

Trends in pharmacological sciences, 32(12), 700-707 (2011-09-29)

Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in

查看所有相关文献